Biotech Startups

Mimark is a biotechnology company developing diagnostic tools for gynecological diseases through biomarker research. The company aims to make testing less invasive and more precise for patients, clinicians, hospitals, and diagnostic manufacturers.

3 investors

Mimio makes a daily supplement built from fasting metabolites that aims to recreate the cellular health and longevity benefits of prolonged fasting without requiring users to fast. The consumer product is positioned around autophagy support, healthy aging, appetite control, and metabolic health.

3 investors

MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain. Its lead candidate, MITI-101, is a monoclonal antibody that blocks a key receptor to prevent neuroinflammation, neurite damage, and vascular pathology, with human trials planned for early 2027.

3 investors

Mindpeak develops AI-powered diagnostic software for cancer pathology, translating complex tissue data into clinical insights to support treatment decisions. The company serves pathologists and clinical institutions working in cancer diagnostics and drug development.

3 investors

Targeting mitochondria for neurodegenerative disease therapies.

3 investors

Mitra develops a non-invasive skin diagnostics platform that combines clinical trials, skin sampling, next-generation sequencing, and data science to guide the design of age-rejuvenating skincare compounds. The company applies genomics to skin health and precision dermatological therapies.

3 investors

Modifi Bio presents itself as a research-focused biopharmaceutical company developing medicines and vaccines. It provides information for patients, investors, and communities and highlights its drug pipeline and clinical trials.

3 investors

Molecule.one applies machine learning to chemical synthesis, predicting synthetic routes and supporting chemistry research with an in-house synthetic and analytical laboratory. It serves pharmaceutical and life-science research through its computational and experimental chemistry platform.

3 investors

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

3 investors

Monument Biosciences is a biotechnology company developing disease-modifying drugs for Alzheimer's Disease and Related Dementias (ADRD). It explores diverse therapeutic modalities and combination therapies targeting neurodegeneration for patients and their families.

3 investors

Pioneering precision epigenetic medicines

3 investors

Mootral developed natural feed supplements that reduce enteric methane emissions from ruminant livestock and built a carbon-credit financing model (the CowCredit) to pay farmers for verified methane reductions. Its core supplement used garlic and citrus bioactives to cut methane intensity in cattle, serving dairy and beef farmers, brands, and carbon markets.

3 investors

MultiplexDX develops a molecular diagnostics platform for cancer detection using proprietary technologies that combine histopathology, biomarker quantification, and gene expression analysis. The company serves research institutions and clinical laboratories internationally, with a focus on improving diagnostic accuracy in oncology.

3 investors

Mycologics develops natural product-based biofungicides derived from microbial sources for broad-spectrum crop disease control, serving agricultural growers. Its formulations target harmful fungal pathogens across multiple crop systems while sparing beneficial organisms, and can be used alone or alongside chemical treatments to manage fungicide resistance.

3 investors

Mynvax develops engineered protein subunit vaccines using a protein stabilization platform, including influenza vaccine candidates based on stabilized hemagglutinin regions and thermo-tolerant vaccines against SARS-CoV-2 variants. Incubated at the Indian Institute of Science, the biotech startup collaborates with research labs, CDMOs, and vaccine manufacturers, with some programs funded by Indian government agencies.

3 investors

MyoKardia was a clinical-stage biopharmaceutical company using precision medicine and genomics to develop targeted small-molecule treatments for genetic cardiovascular diseases, including the drug mavacamten for hypertrophic cardiomyopathy.

3 investors

Myoridge develops serum-free cell culture media and optimization services for cell cultivation and regenerative medicine applications. The company provides media formulations, consulting, and in vitro model development support to organizations conducting biotechnology research and cell therapy product development.

3 investors

NaDeNo develops nanoparticle drug delivery technology that encapsulates hard-to-deliver molecules through a proprietary one-step process without chemical modification. The platform serves pharmaceutical companies and biotech partners seeking to improve formulation of poorly soluble or hydrophobic therapeutics.

3 investors

Nagi Bioscience provides in vivo toxicity testing services using organism-on-chip technology with C. elegans models, serving pharmaceutical, chemical, and biotech companies seeking faster, ethical alternatives to traditional animal testing. The company delivers high-throughput developmental, reproductive, and eco-toxicity assays aligned with regulatory frameworks.

3 investors

Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.

3 investors

3 investors

Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.

3 investors

DermaLayr develops a transdermal delivery platform using ultrafine bioactive nanofibres to enable active ingredients to penetrate deeper into skin. The company serves the beauty and skincare industry with a dry active film technology for topical treatments.

3 investors

NanoSyrinx develops a technology platform for biopharmaceutical applications, with expertise in drug discovery, cell therapy, and biologic development. The company serves biotech and pharmaceutical customers working on therapeutics and medical treatments.

3 investors